METHOD AND COMPOSITIONS FOR ENHANCED ANTI-TUMOR EFFECTOR FUNCTIONING OF T CELLS

摘要

Integration of costimulatory signaling domains within a tumor targeting chimeric antigen receptor (CAR), such as the IL13Ra2 specific IL13-zetakine (IL13?), enhances T cell-mediated responses against tumors even in the absence of expressed ligands for costimulatory receptors.